BioTelemetry (BEAT) Stock Sinks As Market Gains: What You Should Know

A generic image of money and a calculator
Credit: Shutterstock photo

BioTelemetry (BEAT) closed the most recent trading day at $68.16, moving -1.91% from the previous trading session. This change lagged the S&P 500's 0.76% gain on the day. Meanwhile, the Dow gained 0.67%, and the Nasdaq, a tech-heavy index, added 0.71%.

Heading into today, shares of the heart monitoring device maker had gained 17.68% over the past month, outpacing the Medical sector's loss of 1.02% and the S&P 500's gain of 0.75% in that time.

Wall Street will be looking for positivity from BEAT as it approaches its nex t earnings report date. This is expected to be February 28, 2019. On that day, BEAT is projected to report earnings of $0.42 per share, which would represent year-over-year growth of 31.25%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $103.02 million, up 12.29% from the year-ago period.

Any recent changes to analyst estimates for BEAT should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. BEAT currently has a Zacks Rank of #1 (Strong Buy).

In terms of valuation, BEAT is currently trading at a Forward P/E ratio of 39.04. This represents a premium compared to its industry's average Forward P/E of 19.94.

Investors should also note that BEAT has a PEG ratio of 3.9 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. BEAT's industry had an average PEG ratio of 1.54 as of yesterday's close.

The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 100, putting it in the top 40% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

BioTelemetry, Inc. (BEAT): Free Stock Analysis Report

To read this article on click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos


Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

Learn More